- DKK101.26bn
- DKK126.40bn
- $3.72bn
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss
Europe Research Roundup: ACS, Endeavour Mining, IHG
Denmark's Genmab Q1 operating profit misses estimates
Brief: Genmab Reports Q1 Operating Profit Of $180 Million
Europe Research Roundup: Barclays, Societe Generale, UBS Group
GS ups Genmab to 'buy' on attractive entry point ahead of catalysts
Europe Research Roundup: Barclays, Societe Generale, UBS Group
Brief: Genmab Q1 Darzalex Net Sales At $3,964 Mln
Brief: Genmab Says Phase 1/2 Rainfol-01 Data Show Rina-S And Bevacizumab Combination Tolerable
Brief: Genmab Says Orbis Controls 4.99% Of Genmab A/S Voting Rights As Of March 27
Brief: Genmab Completed Share Buy-Back Program On March 13
Novo Nordisk nominates Jan van de Winkel and Ramona Sequeira to board (updated)
Genmab slides as 'disappointing' 2026 outlook outweighs Q4 results
Brief: Genmab FY Oper Profit Up At $1,065 Mln
Brief: Genmab Announces Initiation of Share Buy-Back Program
Brief: Genmab Outlook FY Revenue USD 4,065-4,395 Million